drugset / Trial / NCT00659841

To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)

NCT00659841

Phase 3 Completed 302 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.

Timeline

Start
2003-12
Primary completion
2004-12
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ciclesonide Other / unclassified 200 ug Intranasal